The Opportunity
Saudi Arabia imports the vast majority of its molecular diagnostics. Vision 2030 calls for sovereign, high-quality manufacturing of critical health technologies.
GENE MATRIXManufactured in Saudi Arabia
Pioneering the Future of Molecular Diagnostics in Saudi Arabia
Gene Matrix is the Kingdom's first integrated GMP facility for locally-manufactured PCR diagnostic reagents — built against six international quality frameworks and aligned with Saudi Vision 2030.
- Cleanroom
- 700 m²
- ISO 5 Grade A within ISO 7
- Compliance
- SFDA · ISO
- 13485 · WHO GMP aligned
- Vision 2030
- Localised
- Health Sector Strategy
20+
Years of clinical & molecular leadership
700 m²
GMP cleanroom in Jeddah
4
Flagship PCR kits in Phase 1
1,000+
Healthcare professionals trained
Standards & Alignments
- SFDA
- ISO 9001
- ISO 13485
- WHO GMP
- CE-IVDR
- ISO 5 Grade A
- Vision 2030
Gene Matrix in One Page
A national diagnostics capability — in five lines
The opportunity, the facility, the portfolio, the leadership, and the partnerships we are building.
What we built
A 700 m² GMP facility in Modon Oasis, Jeddah — ISO 5 (Grade A) cleanroom inside ISO 7 (Grade C), aligned with SFDA · ISO 13485 · WHO GMP.
What we make
Four flagship multiplex PCR kits: HPV (14 high-risk genotypes), STI 12-Panel, Dengue (DENV 1–4), and Colorectal & Pancreatic ctDNA.
Who leads
Founded and led by Dr. Burhan Fakhurji — Saudi biotechnology pioneer, academic, and serial entrepreneur with 20+ years across virology, molecular biology, genomics, and medical innovation.
What we're building
Distribution, hospital and tech-transfer partnerships across the GCC and MENA — and a long-term centre of excellence for molecular diagnostics in Jeddah.
Why Gene Matrix
Built for the Kingdom. Trusted by clinicians.
A focused PCR manufacturer combining national priority, scientific rigour, and a regulated quality system — from a single GMP facility in Jeddah.
Health Sovereignty
Reducing dependency on imported diagnostics by manufacturing high-quality PCR kits at home — strengthening Saudi Arabia's resilience against disease outbreaks and supply-chain risk.
Validated Science
Multiplex real-time PCR designed and validated against international clinical references — including HPV genotyping, dengue serotyping, an STI 12-panel, and oncology ctDNA assays.
Strategic Alignment
Built in line with the Saudi Vision 2030 Health Sector Strategy, the Localisation Programme, and the National Industrial Development & Logistics Programme (NIDLP).
Diagnostics Portfolio
Four flagship PCR kits, manufactured in-Kingdom
A focused Phase 1 portfolio aligned with national priorities — women's health, sexual health, public health, and oncology.
Women's Health
HPV Detection Kit
14 high-risk genotypes
Multiplex real-time PCR for HPV detection across 14 high-risk genotypes — supporting cervical-cancer screening pathways.
View kit details
Sexual Health
STI 12-Panel
Twelve sexually transmitted infections
A single multiplex assay covering twelve clinically relevant STI targets — designed for high-throughput laboratory workflows.
View kit details
Public Health
Dengue Detection
DENV-1, 2, 3 and 4 serotypes
Real-time PCR for differential detection of all four dengue serotypes — strengthening Hajj-season surveillance and outbreak response.
View kit details
Oncology
Colorectal & Pancreatic ctDNA
Liquid biopsy for oncology
Circulating tumour DNA assay supporting non-invasive monitoring in colorectal and pancreatic oncology pathways.
View kit details
Modon Oasis · Jeddah · KSA
Factory & Quality
A dedicated GMP facility for in-Kingdom PCR manufacturing
Gene Matrix operates a 700 m² Good Manufacturing Practice facility designed around an ISO 5 (Grade A) critical zone within an ISO 7 (Grade C) background. Every kit is built under a regulated quality system aligned with SFDA, ISO 13485 and WHO GMP.
- 700 m²
- GMP cleanroom footprint
- ISO 5 / 7
- Grade A within Grade C
- Modon Oasis
- Jeddah industrial zone
Vision 2030 · Localisation
National health sovereignty, manufactured at home.
Gene Matrix supports the Kingdom's strategic objective of localising medical-device manufacturing — reducing reliance on imports, building domestic scientific capacity, and contributing to the Health Sector Strategy of Saudi Vision 2030.
Aligned with the National Industrial Development & Logistics Programme (NIDLP) and the Localisation Programme.
Get In Touch
Three ways to engage with Gene Matrix
Whether you're sourcing diagnostics, scaling a partnership, or evaluating an investment, we'll route your enquiry to the right team.
Hospitals & Laboratories
Request a quote for our PCR kits and discuss platform compatibility, validation data and supply.
Request a QuoteDistribution Partners
Explore distribution and clinical partnership opportunities across the GCC and MENA region.
Partner With UsInvestors
Engage with Gene Matrix's institutional growth story and request our investor briefing materials.
Investor Enquiry